Figure 3
AIF-1 mRNA levels in relation to adiposity in (a) abdominal subcutaneous WAT, and (b) visceral WAT (cohort 3, n = 23 obese women, 42 ± 10 years, 44 ± 4 kg/m 2 , n = 12 non-obese women, 40 ± 13 years, 24 ± 2 kg/m 2 ), and (c) in abdominal subcutaneous WAT of obese women (cohort 4, n = 10, 39 ± 6 years, 40 ± 6 kg/m 2 ) before and 2–4 years after intense anti-obesity therapy when they had reached a non-obese weight-stable state. Statistical differences were analyzed by un-paired (a and b) or paired t-test (c). **P < 0.01.